ArticleMedicine2026
Does the treatment concept of advanced gastric cancer require innovation?: Two cases of advanced gastric cancer with distinctively different outcomes.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleWith the continuous progress of science and technology, remarkable achievements have been made in the treatment of gastric cancer (GC). In China, the vast majority of GC patients are diagnosed with advanced GC at the time of initial detection. Given its high incidence and mortality rates, GC poses a serious threat to the health of the Chinese population. The selection of appropriate treatment strategies for patients with advanced GC remains a controversial and challenging issue in clinical practice. PATIENT CONCERNS: Two patients diagnosed with advanced GC experienced drastically different prognoses due to the adoption of disparate treatment modalities. DIAGNOSES: One patient, at stage IIIA, another patient at stage IIB.
interventionsThe stage IIIA patient received neoadjuvant chemotherapy followed by surgical resection, and the stage IIB patient underwent direct surgical resection. OUTCOMES: The patient who received neoadjuvant therapy and surgery has remained free of recurrence so far. In contrast, the direct surgery one unfortunately succumbed to tumor recurrence 1 year after the operation. LESSONS: These 2 patients with the same diagnosis of advanced GC presented strikingly different outcomes, which prompted us to deeply contemplate the optimal treatment approaches for this disease. This paper aims to provide valuable references for the treatment selection of advanced GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.